Biota was the brains and GSK was the backing that brought the world Relenza.
They both thought the world would recognise the advantage of an inhaled (and injectable) antiviral designed purely to defeat influenza, over (in order of importance to Gilead/Roche)an antiviral easy to take (swallow), designed to work around BTA patents, that could be fast-tracked into production, that was invented in the only country that counts (America), and defeats most influenza strains.
However I think your timing is correct because Tamiflu resistance is an immediate threat that can no longer be ignored.
P.S. In the thirty+ years it's taken to reach this moment in time Biota's brains have turned to pampered mush (hat tip to Peter our CEO), GSK decided it was all too hard and backed vaccines instead, but more importantly, NO RESISTANT VIRUS has yet been isolated from a Relenza-treated immunocompetent patient.
- Forums
- ASX - By Stock
- BTA
- exponential growth
exponential growth, page-2
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online